Genovis adds value to the NIMT™ - technology via acquisition of patents and opens a new business area for Genovis products
Genovis, a company that develops and markets innovative tools for medical cell research, has entered into an agreement with Hansa Medical, a subsidiary of Biolin, concerning the acquisition of patent and license rights to a group of bacterial surface proteins for biotechnical industrial applications. Genovis will be marketing the acquired proteins together with the company’s nanoparticles, NIMT™ FeOdots, in completely new products intended for preclinical research. The proteins will predominantly be used as components in products intended for antibody-based research and for the production of antibody fragment. The company is projecting that it will be able to launch these new products in conjunction with the opening of its web shop in September.
“Our goal is to market our nanopaticle technology and know-how under the NIMT™ trademark in applications where there is an obvious need for improved technologies,” says Sarah Fredriksson, the CEO of Genovis. Via the acquisition, we will access several attractive and useful building blocks for use in a series of products suitable for protein research.
The acquisition of the patent rights is a part of the strategy being pursued by Genovis of continually working with the safeguarding and expansion of its existing patent portfolio. The purchase sum will amount to SEK 2 million in cash reimbursement as well as a royalty on the future sales of products by Genovis.
Via the acquisition, Genovis will be active in four business areas: gene transfer, RNA interference, magnetic labeling and sorting of cells and protein research.
“The acquisition in combination with our core competence in biochemistry and molecular biology means that we will shortly be able to expand and supplement our offerings to our customers, first and foremost to customers involved with preclinical research,” says Sarah Fredriksson, the CEO of Genovis. There is a great interest in new techniques and reagens that can facilitate the development of antibody-based medicines. Our ambition is to launch these new products in conjunction with the opening of our web shop in September.
The intangible assets in Hansa Medical’s portfolio are built on the basis of extensive research concerning bacterial surface proteins. Hansa Medical is a wholly owned subsidiary of Biolin AB, which is listed on the Stockholm Stock Exchange.
Bo Håkansson is the Chairman of the Board for Biolin AB and a Board Member for Genovis AB. He declared himself to be disqualified from taking part in the matter, and hence participated neither in the decision nor in the preparation of the deal.